10-K: 180 Life Sciences Corp. Reports 2023 Annual Results, Navigates Financial Challenges and Strategic Review
Sentiment:
Annual Results
180 Life Sciences Corp., a clinical-stage biotech company, released its 2023 annual report, highlighting ongoing research and development efforts amidst financial constraints and a strategic review process.
Delay expectedThe company's Frozen Shoulder trial was closed for further recruitment due to delays in gaining approvals and slow recruitment.
Capital raiseThe company's cash balance is expected to fund operations only through approximately May 2024, necessitating additional financing.The company is exploring strategic alternatives, including a potential acquisition, merger, or sale of assets, to enhance shareholder value.The company plans to seek to raise funding in the future to support its operations, and to pay amounts due to Oxford, through a combination of equity offerings, debt financing or other capital sources, including potentially collaborations, licenses and other similar arrangements.
Worse than expectedThe company's cash balance is expected to fund operations only through approximately May 2024, necessitating additional financing.The company reported a net loss of $19.9 million for the year ended December 31, 2023.The company is not in compliance with the minimum stockholders equity requirement for continued listing on the Nasdaq Capital Market and its common stock and public warrants are subject to delisting.
Summary
- 180 Life Sciences Corp., a clinical-stage biotechnology company, reported its financial results for the year ended December 31, 2023, showing a net loss of $19.9 million.
- The company's cash balance is expected to fund operations only through approximately May 2024, necessitating additional financing.
- The company is exploring strategic alternatives, including a potential acquisition, merger, or sale of assets, to enhance shareholder value.
- Research and development expenses were $2.3 million, while general and administrative expenses totaled $10.6 million for the year.
- The company terminated its HMGB1 license agreement with Oxford University to focus on its anti-TNF platform.
- A reverse stock split of 1-for-19 was implemented in February 2024 to regain compliance with Nasdaq listing requirements.
- The company is currently in discussions with Oxford University to reduce amounts owed and enter into a payment plan.
- The company is planning a Phase 2 trial for post-operative cognitive decline and a Phase 2 trial for frozen shoulder.
- The company is seeking a meeting with the U.S. FDA to explore a pathway towards a pre-IND application.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and strategic planning, the company's financial challenges and need for additional funding create significant uncertainty and risk.
Positives
- The company completed a Phase 2b clinical trial for Dupuytrens Contracture, showing statistically significant differences in nodule hardness and size.
- The company is planning a Phase 3 trial for Dupuytrens Contracture to support a Conditional Marketing Authorization (CMA) application in the U.K.
- The company is seeking a meeting with the U.S. FDA to explore a pathway towards a pre-IND application.
- The company implemented a 1-for-19 reverse stock split in February 2024 to regain compliance with Nasdaq listing requirements.
Negatives
- The company's cash balance is expected to fund operations only through approximately May 2024, necessitating additional financing.
- The company reported a net loss of $19.9 million for the year ended December 31, 2023.
- The company is currently in discussions with Oxford University to reduce amounts owed and enter into a payment plan.
- The company terminated its HMGB1 license agreement with Oxford University to focus on its anti-TNF platform.
Risks
- The company's ability to continue as a going concern is dependent on obtaining additional financing.
- The company faces risks associated with clinical trial delays, regulatory approvals, and commercialization of its product candidates.
- The company is subject to intense competition from companies with greater resources and experience.
- The company may not be able to adequately protect its intellectual property.
- The company is subject to risks associated with the COVID-19 pandemic and other potential future pandemics.
- The company is subject to risks associated with global conflicts, including the ongoing Ukraine/Russian and Israel/Hamas conflicts.
- The company is not in compliance with the minimum stockholders equity requirement for continued listing on the Nasdaq Capital Market and its common stock and public warrants are subject to delisting.
- The company may be subject to litigation and damages for its failure to pay amounts due to Oxford, and may be forced to pay interest and penalties, which funds it does not currently have.
Future Outlook
The company plans to continue its research and development efforts, seek regulatory approvals for its product candidates, and explore strategic alternatives to enhance shareholder value. The company is planning a Phase 3 trial for Dupuytrens Contracture, a Phase 2 trial for post-operative cognitive decline and a Phase 2 trial for frozen shoulder. The company is seeking a meeting with the U.S. FDA to explore a pathway towards a pre-IND application.
Management Comments
- The Board of Directors and management team are committed to acting in the best interests of the Company, its stockholders and its stakeholders.
- The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate.
Industry Context
The company operates in the competitive biotechnology industry, facing challenges from larger companies with greater resources. The company is focused on developing novel therapies for chronic pain, inflammation, and fibrosis, areas with significant unmet medical needs.
Comparison to Industry Standards
- The company's financial results are typical for a clinical-stage biotechnology company, with significant research and development expenses and no current revenue.
- The company's focus on anti-TNF therapies aligns with a well-established and large market, but it faces competition from biosimilars and other treatments.
- The company's development of synthetic cannabinoid analogs is a novel approach, but it faces competition from companies developing plant-derived cannabinoid therapies.
- The company's 7nAChR platform is a less common approach, and its success is highly dependent on preclinical and clinical trial results.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board Member | Donald A. McGovern, Jr. | December 17, 2023 | Resignation due to health reasons. | |
| Board Member | Francis Knuettel II | December 17, 2023 | Resignation due to a difference of opinion on cost cutting initiatives. | |
| Board Member | Pam Marrone | December 17, 2023 | Resignation due to a difference of opinion on cost cutting initiatives. | |
| Board Member | Teresa DeLuca | December 17, 2023 | Resignation due to a difference of opinion on cost cutting initiatives. | |
| Board Member | Larry Gold | December 17, 2023 | Resignation due to a difference of opinion on cost cutting initiatives. | |
| Board Member | Russell Ray | December 17, 2023 | Resignation due to a difference of opinion on cost cutting initiatives. | |
| Board Member | Blair Jordan | February 28, 2024 | New appointment to the Board. | |
| Board Member | Omar Jimenez | March 7, 2024 | New appointment to the Board. | |
| Board Member | Ryan L. Smith | March 7, 2024 | New appointment to the Board. | |
| Board Member | Sir Marc Feldmann | March 7, 2024 | Resignation from the Board. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reverse Stock Split | A 1-for-19 reverse stock split was implemented in February 2024 to regain compliance with Nasdaq listing requirements. | February 28, 2024 | The reverse stock split was intended to increase the per-share price of the company's common stock and regain compliance with Nasdaq listing requirements. The reverse split did not change the authorized number of shares of common stock or preferred stock. |
Legal Proceedings
- The company is involved in ongoing litigation with Dr. Marlene Krauss, Tyche Capital LLC, and Ronald and Samantha Bauer, as well as a declaratory relief action with AmTrust International Underwriters DAC.
- The company is seeking payment for a substantial portion of such amounts from its director and officers insurance policy, of which no assurance can be provided that the directors and officers insurance policy will cover such amounts.
- The company is currently in ongoing discussions with Oxford to reduce that amount and enter into a payment plan with regards to the amounts owed, and has received preliminary acceptance of a payment plan; however, no definitive terms or extensions have been agreed to date. Oxford has also notified the Company that it is not willing to discuss any new projects or arrangements until all outstanding invoices have been paid or a payment plan has been agreed to; has engaged a law firm to seek the collection of the amounts owed, together with interest; and has threatened legal proceedings against us.
Related Party Transactions
- The company has ongoing consulting agreements with Prof. Jagdeep Nanchahal, Prof. Sir Marc Feldmann, and Dr. Lawrence Steinman, who are considered related parties.
- The company has a sub-license agreement with Petcanna Pharma Corp., a private company with one common principal with the Company.
Stakeholder Impact
- Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial challenges.
- Employees may be affected by potential cost-cutting measures and changes in the company's strategic direction.
- Customers and partners may experience delays or disruptions in the company's product development and commercialization efforts.
- Suppliers and creditors may face uncertainty regarding the company's ability to meet its financial obligations.
Next Steps
- The company plans to continue its research and development efforts.
- The company plans to seek regulatory approvals for its product candidates.
- The company plans to explore strategic alternatives to enhance shareholder value.
- The company is planning a Phase 3 trial for Dupuytrens Contracture.
- The company is planning a Phase 2 trial for post-operative cognitive decline.
- The company is planning a Phase 2 trial for frozen shoulder.
- The company is seeking a meeting with the U.S. FDA to explore a pathway towards a pre-IND application.
Key Dates
| Date | Description |
|---|---|
| December 15, 2022 | Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split. |
| December 19, 2022 | The 1-for-20 reverse stock split became effective. |
| February 16, 2024 | Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split. |
| February 28, 2024 | The 1-for-19 reverse stock split became effective. |
| March 5, 2024 | Original deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2). |
| March 13, 2024 | Company received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing. |
| May 13, 2024 | Deadline to complete certain transactions to regain compliance with Nasdaq Listing Rule 5550(b)(1). |
Keywords
biotechnology, clinical trials, Dupuytrens Contracture, anti-TNF, fibrosis, inflammation, cannabinoids, regulatory approval, financial results, strategic review, reverse stock split, Nasdaq compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.